Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sports | 1 | 2016 | 55 | 0.520 |
Why?
|
| Patient Compliance | 2 | 2015 | 402 | 0.490 |
Why?
|
| Poverty | 1 | 2016 | 218 | 0.490 |
Why?
|
| Health Behavior | 3 | 2014 | 458 | 0.480 |
Why?
|
| Sample Size | 1 | 2013 | 79 | 0.450 |
Why?
|
| ROC Curve | 2 | 2013 | 392 | 0.450 |
Why?
|
| Weight Loss | 1 | 2014 | 319 | 0.390 |
Why?
|
| Exercise | 2 | 2016 | 658 | 0.370 |
Why?
|
| Asthma | 4 | 2015 | 345 | 0.340 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2015 | 186 | 0.320 |
Why?
|
| HIV Infections | 5 | 2015 | 775 | 0.300 |
Why?
|
| Parkinson Disease | 3 | 2015 | 272 | 0.290 |
Why?
|
| Obesity | 1 | 2014 | 1074 | 0.280 |
Why?
|
| Medication Adherence | 3 | 2015 | 335 | 0.280 |
Why?
|
| Colonoscopy | 3 | 2016 | 156 | 0.270 |
Why?
|
| Colorectal Neoplasms | 3 | 2016 | 560 | 0.270 |
Why?
|
| Supranuclear Palsy, Progressive | 2 | 2015 | 6 | 0.240 |
Why?
|
| Social Support | 3 | 2016 | 423 | 0.220 |
Why?
|
| Guideline Adherence | 2 | 2016 | 285 | 0.220 |
Why?
|
| Anti-HIV Agents | 3 | 2015 | 135 | 0.220 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2015 | 92 | 0.210 |
Why?
|
| Chicago | 3 | 2016 | 30 | 0.190 |
Why?
|
| Area Under Curve | 4 | 2015 | 238 | 0.190 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 439 | 0.190 |
Why?
|
| Female | 20 | 2016 | 38021 | 0.180 |
Why?
|
| Accelerometry | 2 | 2016 | 61 | 0.160 |
Why?
|
| Child | 8 | 2016 | 6401 | 0.150 |
Why?
|
| Adolescent | 9 | 2016 | 8904 | 0.150 |
Why?
|
| Male | 17 | 2016 | 37283 | 0.150 |
Why?
|
| Humans | 21 | 2016 | 68549 | 0.140 |
Why?
|
| Play and Playthings | 1 | 2016 | 22 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2016 | 63 | 0.130 |
Why?
|
| Tenofovir | 1 | 2015 | 10 | 0.130 |
Why?
|
| Safety | 1 | 2016 | 145 | 0.130 |
Why?
|
| HIV Protease Inhibitors | 1 | 2015 | 25 | 0.130 |
Why?
|
| Colorectal Surgery | 1 | 2015 | 11 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 109 | 0.130 |
Why?
|
| Body Mass Index | 2 | 2016 | 866 | 0.130 |
Why?
|
| Adenoma | 1 | 2016 | 132 | 0.120 |
Why?
|
| Health Promotion | 2 | 2016 | 407 | 0.120 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 2265 | 0.120 |
Why?
|
| Substantia Nigra | 1 | 2015 | 102 | 0.120 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2011 | 35 | 0.120 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 99 | 0.120 |
Why?
|
| Safety-net Providers | 1 | 2014 | 20 | 0.120 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 56 | 0.120 |
Why?
|
| Gastroenterology | 1 | 2015 | 98 | 0.120 |
Why?
|
| Water | 1 | 2015 | 228 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2016 | 252 | 0.120 |
Why?
|
| Multiple System Atrophy | 1 | 2013 | 1 | 0.110 |
Why?
|
| Reference Standards | 1 | 2013 | 115 | 0.110 |
Why?
|
| Biostatistics | 1 | 2013 | 43 | 0.110 |
Why?
|
| Essential Tremor | 1 | 2013 | 8 | 0.110 |
Why?
|
| Pediatric Obesity | 1 | 2014 | 92 | 0.110 |
Why?
|
| Basal Ganglia | 1 | 2013 | 45 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 349 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 160 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2014 | 631 | 0.100 |
Why?
|
| Cerebellum | 1 | 2013 | 103 | 0.100 |
Why?
|
| Life Style | 1 | 2014 | 338 | 0.100 |
Why?
|
| Health Education | 1 | 2014 | 279 | 0.100 |
Why?
|
| HIV | 1 | 2012 | 53 | 0.100 |
Why?
|
| Measles Vaccine | 1 | 2011 | 3 | 0.100 |
Why?
|
| Measles | 1 | 2011 | 6 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2011 | 83 | 0.100 |
Why?
|
| Body Composition | 1 | 2012 | 119 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 46 | 0.100 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 65 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2016 | 2356 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 285 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 186 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 121 | 0.090 |
Why?
|
| Pyrimidinones | 1 | 2010 | 26 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 503 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2011 | 132 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 448 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2011 | 211 | 0.090 |
Why?
|
| Mass Screening | 1 | 2015 | 838 | 0.080 |
Why?
|
| Pregnancy Trimester, Third | 3 | 2015 | 39 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 424 | 0.080 |
Why?
|
| Postpartum Period | 3 | 2015 | 67 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2015 | 1040 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 286 | 0.070 |
Why?
|
| Telemedicine | 1 | 2015 | 699 | 0.070 |
Why?
|
| Pregnancy | 4 | 2015 | 2334 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1085 | 0.060 |
Why?
|
| Aged | 6 | 2016 | 14842 | 0.060 |
Why?
|
| Middle Aged | 7 | 2016 | 21119 | 0.060 |
Why?
|
| Brain | 1 | 2015 | 2176 | 0.060 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2015 | 58 | 0.060 |
Why?
|
| Administration, Inhalation | 2 | 2013 | 187 | 0.060 |
Why?
|
| Minority Groups | 2 | 2015 | 196 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 546 | 0.050 |
Why?
|
| Young Adult | 4 | 2015 | 5710 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 689 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2015 | 3703 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 772 | 0.050 |
Why?
|
| Logistic Models | 2 | 2015 | 1419 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 1860 | 0.040 |
Why?
|
| Adult | 5 | 2015 | 21379 | 0.040 |
Why?
|
| United States | 3 | 2015 | 7338 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 67 | 0.030 |
Why?
|
| Documentation | 1 | 2016 | 83 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2015 | 64 | 0.030 |
Why?
|
| Adolescent Health Services | 1 | 2014 | 18 | 0.030 |
Why?
|
| Hand Strength | 1 | 2015 | 47 | 0.030 |
Why?
|
| Television | 1 | 2014 | 28 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 75 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2014 | 44 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2014 | 42 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2011 | 3187 | 0.030 |
Why?
|
| Child Health Services | 1 | 2014 | 50 | 0.030 |
Why?
|
| Smartphone | 1 | 2015 | 69 | 0.030 |
Why?
|
| Health Literacy | 1 | 2014 | 62 | 0.030 |
Why?
|
| MP3-Player | 1 | 2013 | 3 | 0.030 |
Why?
|
| HIV-1 | 1 | 2015 | 177 | 0.030 |
Why?
|
| Oxygen | 1 | 2015 | 386 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2016 | 7268 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 281 | 0.030 |
Why?
|
| Anisotropy | 1 | 2013 | 105 | 0.030 |
Why?
|
| Peer Group | 1 | 2013 | 104 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2015 | 138 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 799 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2014 | 224 | 0.030 |
Why?
|
| Risk Factors | 2 | 2013 | 5720 | 0.030 |
Why?
|
| Sleep | 1 | 2014 | 263 | 0.030 |
Why?
|
| Counseling | 1 | 2014 | 279 | 0.030 |
Why?
|
| Emtricitabine | 1 | 2011 | 5 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2011 | 48 | 0.030 |
Why?
|
| Self Care | 1 | 2014 | 252 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2012 | 83 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 73 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1054 | 0.030 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2011 | 4 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 2011 | 10 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1037 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 955 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2011 | 25 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 219 | 0.020 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2013 | 211 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 1265 | 0.020 |
Why?
|
| Viral Load | 1 | 2011 | 127 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2011 | 98 | 0.020 |
Why?
|
| School Health Services | 1 | 2011 | 72 | 0.020 |
Why?
|
| Social Class | 1 | 2011 | 127 | 0.020 |
Why?
|
| Diet | 1 | 2014 | 514 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 467 | 0.020 |
Why?
|
| Lopinavir | 1 | 2010 | 18 | 0.020 |
Why?
|
| Zidovudine | 1 | 2010 | 27 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2011 | 110 | 0.020 |
Why?
|
| Urban Population | 1 | 2011 | 254 | 0.020 |
Why?
|
| Research Design | 1 | 2014 | 729 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1851 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 929 | 0.020 |
Why?
|
| Students | 1 | 2011 | 233 | 0.020 |
Why?
|
| Gestational Age | 1 | 2010 | 389 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2013 | 1329 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 648 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 554 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 4655 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 711 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1582 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1745 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2222 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 766 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2324 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 2798 | 0.010 |
Why?
|